Literature DB >> 10865011

Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting.

V Marzinotto1, P Monagle, A Chan, M Adams, P Massicotte, M Leaker, M Andrew.   

Abstract

A whole blood prothrombin time/international normalized ratio (PT/INR) monitor (CoaguChek, Roche Diagnostics Corp., Indianapolis, IN) was assessed in children for its accuracy, reliability, safety, and acceptance by health care personnel and patient's families. The PT/INR values measured by the CoaguChek monitor showed an excellent correlation with PT/INR values measured by the Hospital for Sick Children (HSC) laboratory (r = 0.96) and Hamilton Civic Hospitals Research Centre (HCHRC) laboratory (r = 0.92) in clinic patients and a close correlation with PT/INR values measured by the HSC laboratory (r = 0.76) and HCHRC laboratory (r = 0.74) in patients at home. Reduced correlation in the home setting did not adversely affect clinical management. The whole blood PT/INR monitor is safe and accurate for children requiring oral anticoagulation therapy in either the outpatient clinic or home setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10865011     DOI: 10.1007/s002460010078

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  10 in total

1.  Oral anticoagulant thromboprophylaxis for Kawasaki disease.

Authors:  F Newall; P Monagle
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

2.  Validity of CoaguChek S for home monitoring of anticoagulant therapy in pediatrics.

Authors:  James Hill; Sébastien Perreault; Michel Dorval
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

3.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Evaluating safety, effectiveness, and user satisfaction of home international normalized ratio monitoring service: experience from a tertiary pediatric cardiology unit in the United Kingdom.

Authors:  Deepti Bhat; Ajay Upponi; Aditya Rakecha; John Thomson
Journal:  Pediatr Cardiol       Date:  2009-10-06       Impact factor: 1.655

5.  The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.

Authors:  Cornelia Heleen van Ommen; Manuela Albisetti; Anthony K Chan; Jeremie Estepp; Julie Jaffray; Gili Kenet; Guy Young; Jay Dave; Michael A Grosso; Anil Duggal
Journal:  Res Pract Thromb Haemost       Date:  2020-05-25

6.  Vitamin k antagonist warfarin for palliative treatment of metachromatic leukodystrophy, a compassionate study of four subjects.

Authors:  Mitra Assadi; Dah-Jyuu Wang; Kelly Anderson; Melissa Carran; Larissa Bilaniuk; Paola Leone
Journal:  J Cent Nerv Syst Dis       Date:  2012-04-26

Review 7.  International normalized ratio self-testing and self-management: improving patient outcomes.

Authors:  Matteo Pozzi; Julia Mitchell; Anna Maria Henaine; Najib Hanna; Ola Safi; Roland Henaine
Journal:  Vasc Health Risk Manag       Date:  2016-10-12

8.  Acute Ischemic Pediatric Stroke Management: An Extended Window for Mechanical Thrombectomy?

Authors:  Ashish Kulhari; Elizabeth Dorn; Jonathan Pace; Vilakshan Alambyan; Stephanie Chen; Osmond C Wu; Macym Rizvi; Anthony Hammond; Ciro Ramos-Estebanez
Journal:  Front Neurol       Date:  2017-11-29       Impact factor: 4.003

Review 9.  Anticoagulant therapy in pediatrics.

Authors:  Mariam K Dabbous; Fouad R Sakr; Diana N Malaeb
Journal:  J Basic Clin Pharm       Date:  2014-03

10.  International normalized ratio testing with point-of-care coagulometer in healthy term neonates.

Authors:  Shigeo Iijima; Toru Baba; Daizo Ueno; Akira Ohishi
Journal:  BMC Pediatr       Date:  2014-07-09       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.